Whitepaper: SARS-CoV-2 vaccines and biosafety
Posted: 9 December 2020 | Merck | No comments yet
Upholding biosafety standards in coronavirus vaccine development and manufacturing despite the acute worldwide need.
Patient safety comes first. This is particularly important for vaccines, which are also used on healthy individuals. On the basis of the regulatory framework, this article focuses on some of the main challenges in proving that a vaccine is both safe in principle and manufactured in a way that ensures patient safety. It also points to some general obstacles that stand in the way of vaccine development.
Related content from this organisation
- Moderna-Merck & Co cancer vaccine with Keytruda shows late-stage promise
- Raman-based PAT tool could advance continuous vaccine manufacturing
- Merck acquires JSR Life Sciences chromatography business
- MSD acquisition to accelerate first-in-class COPD drug
- Next drug patent cliff to challenge Big Pharma strategy
Related topics
Analytical techniques, Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Regulation & Legislation, Research & Development (R&D)
